{"id":"W2898394782","doi":"10.1093/annonc/mdy424.045","title":"KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":138,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Cetuximab; Carboplatin; Head and neck squamous-cell carcinoma; Internal medicine; Pembrolizumab; Interim analysis; Cisplatin; Phases of clinical research; Oncology; Chemotherapy; Gastroenterology; Head and neck cancer; Radiation therapy; Nuclear medicine; Randomized controlled trial; Urology; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009978946,0.001061775,0.001197286,0.0003821875,0.0004590028,0.001166068,0.001259643,0.001198523,0.005679193],"category_scores_gemma":[0.0005187765,0.000528663,0.001214426,0.0002842563,0.0007139512,0.0009951977,0.0003542376,0.003592681,0.001846303],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001175883,"about_ca_system_score_gemma":0.001769515,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002195814,"about_ca_topic_score_gemma":0.006112364,"domain_scores_codex":[0.9998301,0.00004703866,0.000007116732,0.00003600802,0.00001676133,0.00006279719],"domain_scores_gemma":[0.999732,0.00002957384,0.00003165652,0.00002242639,0.000020002,0.0001643097],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4154126,0.07461377,0.00850151,0.00244386,0.002543561,0.0007082216,0.0006512122,0.005886383,0.1186326,0.00108492,0.02582933,0.3436921],"study_design_scores_gemma":[0.6050066,0.3564255,0.01194475,0.0001023296,0.0009865747,0.000733565,0.0001746665,0.00256222,0.0104569,0.0004735082,0.01107434,0.00005898164],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9829979,0.003578635,0.0008416452,0.001051858,0.000429963,0.002744892,0.003107309,0.0003785772,0.004869307],"genre_scores_gemma":[0.9740217,0.003829818,0.002803878,0.001540623,0.0001772067,0.002518338,0.004816839,0.00007775253,0.01021392],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005679193,"threshold_uncertainty_score":0.0189988,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1053882196610361,"score_gpt":0.416188050832784,"score_spread":0.3107998311717479,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}